| 4 0.01 (0.25%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.67 | 1-year : | 5.45 |
| Resists | First : | 4 | Second : | 4.67 |
| Pivot price | 3.98  |
|||
| Supports | First : | 3.96 | Second : | 3.94 |
| MAs | MA(5) : | 3.99 |
MA(20) : | 3.98 |
| MA(100) : | 2.02 |
MA(250) : | 3.24  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 100 |
D(3) : | 92.5 |
| RSI | RSI(14): 82.6 | |||
| 52-week | High : | 6.23 | Low : | 0.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ INZY ] has closed below upper band by 19.8%. Bollinger Bands are 95.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4 - 4.02 | 4.02 - 4.04 |
| Low: | 3.95 - 3.98 | 3.98 - 4 |
| Close: | 3.97 - 4 | 4 - 4.03 |
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Tue, 01 Jul 2025
BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan
Tue, 01 Jul 2025
BioMarin completes acquisition of Inozyme Pharma, triggers delisting from Nasdaq - Investing.com
Fri, 20 Jun 2025
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders - GlobeNewswire
Mon, 19 May 2025
Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals
Mon, 19 May 2025
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - Yahoo Finance
Fri, 16 May 2025
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 94.2 (%) |
| Shares Short | 3,380 (K) |
| Shares Short P.Month | 3,840 (K) |
| EPS | -1.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.5 % |
| Return on Equity (ttm) | -141.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -2.39 |
| PEG Ratio | 0 |
| Price to Book value | 8.16 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|